ofloxacin has been researched along with ceftazidime in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 12 (57.14) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Apiwattanakul, N; Endou, H; Jariyawat, S; Kanai, Y; Sekine, T; Sophasan, S; Takeda, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Caniça, M; Ferreira, E; Leitão, J; Manageiro, V; Mendonça, N | 1 |
| Bouza, E; Cercenado, E; Coll, P; Gutiérrez, O; Juan, C; Navarro, F; Oliver, A; Pérez, JL | 1 |
| Chen, T; Khalil, H; Riffon, R; Wang, R; Wang, Z | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Badur, S; Cagatay, AA; Carrër, A; Eraksoy, H; Nordmann, P; Poirel, L | 1 |
| Cattoir, V; Nordmann, P; Poirel, L | 1 |
| Hanaki, H; Maseda, H; Nakae, T; Sugimura, M | 1 |
| Fujimoto, S; Ike, Y; Okuzumi, K; Tanimoto, K; Tomita, H | 1 |
| Kirikae, T; Kitao, T; Miyoshi-Akiyama, T | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Girlich, D; Nordmann, P; Poirel, L | 1 |
| Avdeef, A; Sun, N; Tam, KY; Tsinman, O | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Mima, T; Schweizer, HP | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Brown, DG; Gagnon, MM; May-Dracka, TL; Tommasi, R | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, T; Li, Z; Lyu, Y; Shan, A; Shang, L; Yang, Y; Zhu, J | 1 |
1 review(s) available for ofloxacin and ceftazidime
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
20 other study(ies) available for ofloxacin and ceftazidime
| Article | Year |
|---|---|
The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1.
Topics: Animals; Anion Transport Proteins; Anti-Bacterial Agents; Biological Transport; Carrier Proteins; Cell Survival; Cephaloridine; Cephalosporins; In Vitro Techniques; Kidney; Kinetics; Oocytes; p-Aminohippuric Acid; Penicillin G; Rats; Recombinant Proteins; Xenopus laevis | 1999 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Microbial Sensitivity Tests; Middle Aged; Portugal | 2007 |
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Chromosomes, Bacterial; Cross Infection; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Integrons; Molecular Epidemiology; Molecular Sequence Data; Mutation; Plasmids; Polymerase Chain Reaction; Porins; Pseudomonas aeruginosa; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Spain | 2007 |
Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
Topics: Aminoglycosides; Anti-Bacterial Agents; Carbenicillin; Ceftazidime; Ciprofloxacin; Drug Resistance, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests; Novobiocin; Ofloxacin; Piperacillin; Polyethyleneimine; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Ticarcillin; Tobramycin | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Models, Genetic; Turkey | 2008 |
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
Topics: Aged; Base Sequence; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Fluoroquinolones; France; Genes, Bacterial; Humans; Models, Genetic; Molecular Sequence Data; Plasmids | 2008 |
Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Outer Membrane Proteins; Down-Regulation; Humans; Macrolides; Membrane Transport Proteins; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Quorum Sensing | 2008 |
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
Topics: Base Sequence; beta-Lactam Resistance; Carbapenems; DNA Primers; DNA, Bacterial; Doripenem; Fluoroquinolones; Genes, Bacterial; Humans; In Vitro Techniques; Meropenem; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2008 |
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
Topics: Acetylation; Acetyltransferases; Aminoglycosides; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Integrons; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate.
Topics: Acinetobacter baumannii; beta-Lactamases; DNA, Bacterial; Escherichia coli; France; Genes, Bacterial; Water Microbiology | 2010 |
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Topics: Caco-2 Cells; Cell Membrane Permeability; Humans; Hydrogen-Ion Concentration; Membranes, Artificial; Molecular Structure; Pharmaceutical Preparations | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Burkholderia pseudomallei; Culture Media; Drug Resistance, Multiple, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Mutation; Periplasmic Proteins; Quorum Sensing; Singapore; Virulence Factors | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens.
Topics: Anti-Bacterial Agents; Blood Proteins; Drug Resistance, Multiple; Gram-Negative Bacteria; Gram-Positive Bacteria; High-Throughput Screening Assays; Humans; Hydrophobic and Hydrophilic Interactions; Microbial Sensitivity Tests; Protein Binding; Structure-Activity Relationship | 2014 |
Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism.
Topics: Anti-Infective Agents; Antimicrobial Cationic Peptides; Bacterial Outer Membrane; Drug Design; Escherichia coli; Humans; Microbial Sensitivity Tests; Oligopeptides; Peptide Fragments; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Staphylococcus aureus; Tryptophan | 2019 |